LINC00648: A Drug Target / Disease Biomarker (G100506433)

Target Name: LINC00648

NCBI ID: G100506433

LINC00648

Other Name(s): Long intergenic non-protein coding RNA 648 | long intergenic non-protein coding RNA 648 | RP11-479H16.1

LINC00648: A Drug Target / Disease Biomarker

LINC00648 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the T-cell receptor signaling pathway, which is involved in the regulation of immune responses and inflammation. LINC00648 has been identified as a potential drug target due to its unique structure and the involvement of this signaling pathway in a variety of diseases.

The T-cell receptor signaling pathway is a critical regulatory mechanism that plays a role in the development and maintenance of immune function. The pathway consists of several components, including the T-cell receptor itself, the co-stimulatory molecules that activate the receptor, and the signaling molecules that transmit the signal from the receptor to downstream signaling pathways. LINC00648 is a co-stimulatory molecule that has been shown to play a role in the T-cell receptor signaling pathway.

LINC00648 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the T-cell receptor signaling pathway, which is involved in the regulation of immune responses and inflammation.

One of the key functions of LINC00648 is its role as a co-stimulatory molecule in the T-cell receptor signaling pathway. This means that LINC00648 helps to activate the T-cell receptor and recruit it to the cell surface. Once the T-cell receptor is activated, it can interact with several downstream signaling molecules, including the protein PD-L1.

PD-L1 is a protein that is expressed in many different tissues throughout the body, including the immune system. It is a negative regulator of the T-cell receptor, which means that it can prevent the T-cell receptor from being activated and responding to its co-stimulatory molecules. LINC00648 can interact with PD-L1 and prevent it from inhibiting the T-cell receptor, which is a key step in the T-cell receptor signaling pathway.

LINC00648 has been shown to play a role in the regulation of immune responses and inflammation. Studies have shown that LINC00648 is involved in the development of immune tolerance, which is the ability of the immune system to distinguish between self and non-self and avoid attacking the body's own tissues.

In addition to its role in the T-cell receptor signaling pathway, LINC00648 has also been shown to play a role in the regulation of cell survival. Studies have shown that LINC00648 can induce cell death, either through the production of reactive oxygen species (ROS) or through the inhibition of cell survival signaling pathways.

The role of LINC00648 in cell survival is important because it can have a negative impact on the survival and proliferation of cancer cells. Therefore, LINC00648 is a potential drug target that can be targeted with drugs that can inhibit its activity.

In conclusion, LINC00648 is a protein that is expressed in various tissues throughout the body and is involved in the T-cell receptor signaling pathway. Its role as a co-stimulatory molecule in the T-cell receptor signaling pathway and its involvement in the regulation of immune responses and cell survival make it a potential drug target. Further research is needed to fully understand the role of LINC00648 in the regulation of immune responses and to identify potential drugs that can inhibit its activity.

Protein Name: Long Intergenic Non-protein Coding RNA 648

The "LINC00648 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00648 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets